Hormone Therapy Dementia “Black Box” Warning Sought By FDA
Executive Summary
FDA is recommending a hormone replacement therapy class "black box" warning on an increased risk of dementia with use of estrogen and combination estrogen/progestin products
You may also be interested in...
FDA Estrogen Guidance Recommends Labeling Changes On Dementia Risk
FDA is recommending hormone replacement therapy class labeling changes to include new dementia risk information on estrogen-alone therapy in a 1draft guidance on noncontraceptive estrogen drug products
FDA Estrogen Guidance Recommends Labeling Changes On Dementia Risk
FDA is recommending hormone replacement therapy class labeling changes to include new dementia risk information on estrogen-alone therapy in a 1draft guidance on noncontraceptive estrogen drug products
Warner Chilcott Femtrace Launch Expected In First Quarter 2005
Warner Chilcott is planning an early 2005 launch for Femtrace following FDA approval of the hormone replacement therapy Aug. 20